Annandale Capital LLC Invests $502,000 in Medpace Holdings, Inc. $MEDP

Annandale Capital LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,600 shares of the company’s stock, valued at approximately $502,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares in the last quarter. Brooklyn Investment Group grew its holdings in shares of Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock worth $30,000 after buying an additional 71 shares in the last quarter. Employees Retirement System of Texas acquired a new position in shares of Medpace in the second quarter valued at approximately $36,000. IFP Advisors Inc lifted its stake in shares of Medpace by 223.3% during the second quarter. IFP Advisors Inc now owns 194 shares of the company’s stock valued at $61,000 after buying an additional 134 shares during the period. Finally, Hantz Financial Services Inc. lifted its stake in shares of Medpace by 5,075.0% during the second quarter. Hantz Financial Services Inc. now owns 207 shares of the company’s stock valued at $65,000 after buying an additional 203 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Activity at Medpace

In other Medpace news, CEO August J. Troendle sold 668 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the sale, the chief executive officer owned 646,184 shares of the company’s stock, valued at $381,694,426.96. This trade represents a 0.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the sale, the vice president owned 27,500 shares in the company, valued at $16,751,625. This represents a 42.11% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 387,925 shares of company stock worth $233,386,647. 20.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have commented on MEDP. Robert W. Baird set a $613.00 target price on shares of Medpace in a research note on Friday, October 24th. Jefferies Financial Group raised their price objective on Medpace from $400.00 to $450.00 and gave the stock a “hold” rating in a report on Tuesday, September 9th. Rothschild Redb lowered Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 3rd. BMO Capital Markets initiated coverage on Medpace in a research report on Thursday, November 13th. They set a “market perform” rating and a $600.00 target price on the stock. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a research note on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, Medpace has an average rating of “Hold” and a consensus price target of $487.18.

Medpace Trading Down 5.5%

NASDAQ:MEDP opened at $544.77 on Friday. The firm has a market capitalization of $15.35 billion, a price-to-earnings ratio of 38.10, a PEG ratio of 2.17 and a beta of 1.43. The firm’s fifty day simple moving average is $566.87 and its 200 day simple moving average is $451.00. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $626.26.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.36. The firm had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.